Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Glucose + Ascorbic acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 2 · 1992–2026
Showing the 50 most relevant studies, sorted by most relevant.
Plischke H, Sunami Y, Rebelo A, et al.
2026
- Pancreas
- Stromal Cells
- Epithelial Cells
Gholizadeh M, Noushzadeh Z, Movahed S, et al.
2026
BackgroundLeptin plays a key role in regulating energy balance and lipid reserves. Leptin has a broad spectrum of regulatory actions. Adiponectin, an adipokine released by adipocytes, is recognized as an important factor in maintaining balance of blood glucose levels, lipid metabolism and insulin sensitivity. Recent studies have investigated the role of Ascorbic acid (AA) in the management of metabolic syndrome or the effect of high dose AA supplementation on serum AA, leptin and cortisol parameters.PurposeThe purpose of the current systematic review was to identify associations between AA supplementation and plasma leptin and adiponectin level in vivo and in vitro setting.MethodsComprehensive systematic search was performed in the PubMed/Medline, SCOPUS, and Web of Science databases up to 14 May 2026. A total of 948 studies were initially searched, 187 from PubMed, 204 from the Web of Science, and 557 from Scopus databases. After excluding the duplicates, the remaining 435 articles were screened by reviewing the title and abstract, and 411 unrelated articles were excluded. Of the remaining 24 articles, 9 articles met our inclusion/exclusion.ResultsThe results obtained from the in vivo studies show that AA supplementation positively influences the secretion of adiponectin hormone from adipose tissue cells. Moreover, in vivo studies reveal an inverse relationship between AA concentration and leptin secretion, suggesting that AA supplementation may reduce leptin levels. However, human studies present conflicting evidence regarding the effect of AA on leptin levels.ConclusionThis systematic review demonstrates a positive relationship between AA and adiponectin and inverse relationship with leptin.
Abstract licence: CC BY-NC-ND
A. Meister
Biochemical pharmacology, 1992
S. Mason, B. Rasmussen, Luc J. C. van Loon, et al.
Diabetes, 2018
Gitashree Darabdhara, Bhagyasmeeta Sharma, M. Das, et al.
Sensors and Actuators B-chemical, 2017
T. Arakawa, Keisuke Tomoto, Hiroki Nitta, et al.
Analytical chemistry, 2020
Francesca Mazzara, B. Patella, G. Aiello, et al.
Electrochimica Acta, 2021
Athar SS, Ghavamzadeh S, Zayer B, et al.
2026
M. Castro, Felipe A. Beltrán, S. Brauchi, et al.
Journal of Neurochemistry, 2009
H. Tsukaguchi, T. Tokui, B. Mackenzie, et al.
Nature, 1999
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.